Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313373380> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4313373380 endingPage "239.4" @default.
- W4313373380 startingPage "239.4" @default.
- W4313373380 abstract "Abstract Background Autologous immune cell-based therapies to re-activate the immune system have been developed to treat patients with cancer. For example, chimeric antigen receptor T cell (CAR T) therapy is an FDA approved strategy that uses autologous T cells as a cancer treatment. Mast cells (MC) are important immune sentinels and widely recognized for their role as mediators of Type I hypersensitivity. However, they also secrete anti-cancer mediators such as tumor necrosis factor alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) which are being investigated in clinical trials for cancer treatment. Methods We generated adipose-derived mast cells (ADMC) and sensitized with anti-CD20 IgE antibodies and challenged with B-lymphoma cells. In addition, immunocompromised mice were examined for the maximal tolerated dose using ADMC. The ability of the ADMC to be transduced with lentiviral vectors carrying green fluorescence protein was examined. Results It is shown that CD20 IgE-sensitized ADMC bind to and are activated by CD20 positive B-lymphoma cells. The ADMC injected into mice do not display signs of anaphylaxis by the systemic injection of up to 1 × 106 ADMC/mouse. It is also shown for the first time that ADMC and their adipose-derived stem cell precursors can be transduced with a lentiviral vector carrying green fluorescence protein without affecting function. Conclusion This discovery indicates the ADMC could be transduced with other tumor killing molecules to create a “super killing” cell with potent and diverse anti-tumor activity. Using tumor targeting IgE’s, autologous ADMC could be used as a “Trojan Horse” to deliver these anti-tumor mediators to tumors and serve as a new cancer immunotherapy platform." @default.
- W4313373380 created "2023-01-06" @default.
- W4313373380 creator A5047315422 @default.
- W4313373380 creator A5051213631 @default.
- W4313373380 creator A5072326642 @default.
- W4313373380 creator A5083782517 @default.
- W4313373380 creator A5084760419 @default.
- W4313373380 creator A5090355990 @default.
- W4313373380 creator A5091537402 @default.
- W4313373380 date "2020-05-01" @default.
- W4313373380 modified "2023-10-01" @default.
- W4313373380 title "A New Cellular Cancer Immunotherapy Platform Technology Using Autologous Human Adipose-Derived Mast Cells" @default.
- W4313373380 doi "https://doi.org/10.4049/jimmunol.204.supp.239.4" @default.
- W4313373380 hasPublicationYear "2020" @default.
- W4313373380 type Work @default.
- W4313373380 citedByCount "1" @default.
- W4313373380 countsByYear W43133733802023 @default.
- W4313373380 crossrefType "journal-article" @default.
- W4313373380 hasAuthorship W4313373380A5047315422 @default.
- W4313373380 hasAuthorship W4313373380A5051213631 @default.
- W4313373380 hasAuthorship W4313373380A5072326642 @default.
- W4313373380 hasAuthorship W4313373380A5083782517 @default.
- W4313373380 hasAuthorship W4313373380A5084760419 @default.
- W4313373380 hasAuthorship W4313373380A5090355990 @default.
- W4313373380 hasAuthorship W4313373380A5091537402 @default.
- W4313373380 hasConcept C126322002 @default.
- W4313373380 hasConcept C141105273 @default.
- W4313373380 hasConcept C159654299 @default.
- W4313373380 hasConcept C171089720 @default.
- W4313373380 hasConcept C17991360 @default.
- W4313373380 hasConcept C18031839 @default.
- W4313373380 hasConcept C203014093 @default.
- W4313373380 hasConcept C2777701055 @default.
- W4313373380 hasConcept C2780674031 @default.
- W4313373380 hasConcept C502942594 @default.
- W4313373380 hasConcept C71924100 @default.
- W4313373380 hasConcept C8891405 @default.
- W4313373380 hasConceptScore W4313373380C126322002 @default.
- W4313373380 hasConceptScore W4313373380C141105273 @default.
- W4313373380 hasConceptScore W4313373380C159654299 @default.
- W4313373380 hasConceptScore W4313373380C171089720 @default.
- W4313373380 hasConceptScore W4313373380C17991360 @default.
- W4313373380 hasConceptScore W4313373380C18031839 @default.
- W4313373380 hasConceptScore W4313373380C203014093 @default.
- W4313373380 hasConceptScore W4313373380C2777701055 @default.
- W4313373380 hasConceptScore W4313373380C2780674031 @default.
- W4313373380 hasConceptScore W4313373380C502942594 @default.
- W4313373380 hasConceptScore W4313373380C71924100 @default.
- W4313373380 hasConceptScore W4313373380C8891405 @default.
- W4313373380 hasIssue "1_Supplement" @default.
- W4313373380 hasLocation W43133733801 @default.
- W4313373380 hasOpenAccess W4313373380 @default.
- W4313373380 hasPrimaryLocation W43133733801 @default.
- W4313373380 hasRelatedWork W157270364 @default.
- W4313373380 hasRelatedWork W1985667084 @default.
- W4313373380 hasRelatedWork W1988863520 @default.
- W4313373380 hasRelatedWork W2079900469 @default.
- W4313373380 hasRelatedWork W2087982072 @default.
- W4313373380 hasRelatedWork W2107710620 @default.
- W4313373380 hasRelatedWork W2113983184 @default.
- W4313373380 hasRelatedWork W2793246083 @default.
- W4313373380 hasRelatedWork W2864532522 @default.
- W4313373380 hasRelatedWork W3200144870 @default.
- W4313373380 hasVolume "204" @default.
- W4313373380 isParatext "false" @default.
- W4313373380 isRetracted "false" @default.
- W4313373380 workType "article" @default.